Sg3 Management, LLC Crispr Therapeutics Ag Call Options Transaction History

Sg3 Management, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	BUY	$39.19 - $65.67 $4.6 Million - $7.71 Million	117,400 New	117,400 $4.77 Million
Q1 2022 May 16, 2022	SELL	$53.19 - $79.24 $718,065 - $1.07 Million	-13,500 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$70.09 - $111.29 $700,900 - $1.11 Million	-10,000 Reduced 42.55%	13,500 $1.02 Million
Q3 2021 Nov 15, 2021	SELL	$110.2 - $156.64 $2.91 Million - $4.14 Million	-26,400 Reduced 52.91%	23,500 $2.63 Million
Q2 2021 Aug 16, 2021	SELL	$100.84 - $161.89 $20.6 Million - $33 Million	-204,000 Reduced 80.35%	49,900 $8.08 Million
Q1 2021 May 17, 2021	BUY	$110.72 - $210.04 $22.4 Million - $42.5 Million	202,400 Added 393.01%	253,900 $30.9 Million
Q4 2020 Feb 16, 2021	BUY	$79.67 - $173.23 $4.1 Million - $8.92 Million	51,500 New	51,500 $7.89 Million
Q3 2020 Nov 13, 2020	SELL	$78.5 - $100.64 $1.96 Million - $2.52 Million	-25,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$38.5 - $76.05 $962,500 - $1.9 Million	25,000 New	25,000 $1.84 Million

499

56.8M

1.7M

1.8M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.05B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.